Eli Lilly and Company (SNSE:LLYCL)

Market Cap	802.46T +11.9%
Revenue (ttm)	58.71T +44.7%
Net Income	18.59T +94.9%
EPS	20,672.67 +96.0%
Shares Out	n/a
PE Ratio	43.16
Forward PE	29.86
Dividend	5,729.16 (0.63%)
Ex-Dividend Date	Feb 13, 2026

Volume	2
Average Volume	2
Open	908,800
Previous Close	903,910
Day's Range	908,800 - 910,000
52-Week Range	608,400 - 1,034,500
Beta	n/a
RSI	16.89
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: LLYCL

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD